Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:dateCreated |
1998-12-10
|
| pubmed:abstractText |
The presence of residual host cell proteins in protein pharmaceuticals obtained from continuous mammalian cell lines has been a point of concern. Clinical experience with different biopharmaceuticals shows that residual protein in these highly purified products does not represent a danger to the health of the patients.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0301-5149
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
93
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
61-4
|
| pubmed:dateRevised |
2005-11-16
|
| pubmed:meshHeading | |
| pubmed:year |
1998
|
| pubmed:articleTitle |
Residual host cell protein from continuous cell lines. Effect on the safety of protein pharmaceuticals.
|
| pubmed:affiliation |
Sanofi Recherche, Centre de Labège, France.
|
| pubmed:publicationType |
Journal Article,
Review
|